PharmaShots | Incisive News in 3 Shots

Subscribe Now

taiho oncology

Insights+: The US FDA New Drug Approvals in August 2023

Insights+: The US FDA New Drug Approvals in August 2023

September 21, 2023

Taiho Oncology and Taiho Pharmaceutical Receive the US FDA’s Approval of Lonsurf (trifluridine/tipiracil) for Adult with Metastatic Colorectal Cancer

Taiho Oncology and Taiho Pharmaceutical Receive the US FDA’s Approval of Lonsurf (trifluridine/tipiracil) for Adult with Metastati...

August 3, 2023

$Taiho Oncology Reports the US FDA Acceptance of sNDA for Priority Review of Lonsurf (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer$

Taiho Oncology Reports the US FDA Acceptance of sNDA for Priority Review of Lonsurf (trifluridine and tipiracil) for Refractory Me...

April 19, 2023

Taiho Oncology Publishes P-II Trial (FOENIX*-CCA2) Results of Futibatinib for Metastatic Intrahepatic Cholangiocarcinoma in NEJM

Taiho Oncology Publishes P-II Trial (FOENIX*-CCA2) Results of Futibatinib for Metastatic Intrahepatic Cholangiocarcinoma in NEJM

January 19, 2023

Taiho Oncology Reports the US FDA’s Acceptance of NDA for Priority Review of Futibatinib for the Treatment of Cholangiocarcinoma

Taiho Oncology Reports the US FDA’s Acceptance of NDA for Priority Review of Futibatinib for the Treatment of Cholangiocarcinoma

March 31, 2022

PharmaShots Weekly Snapshots (April 05 - 09, 2021)

PharmaShots Weekly Snapshots (April 05 - 09, 2021)

April 9, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us